Related Experiment Video

Updated: Aug 29, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

The patient with diabetes mellitus and heart failure: at-risk issues

Thomas D Giles1

  • 1Section of Cardiovascular Research, Louisiana State University Health Science Center, New Orleans, Louisiana 70112, USA.

The American Journal of Medicine
|December 18, 2003
PubMed

Insights

Patients with type 2 diabetes have higher cardiovascular risks. Thiazolidinediones (TZDs) may offer cardiovascular benefits for these patients, but their use requires careful risk-benefit consideration due to potential side effects like fluid retention.

Area of Science:

  • Endocrinology
  • Cardiology
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) significantly elevates cardiovascular disease risk, especially heart failure.
  • Hyperglycemia and insulin resistance in T2DM are linked to myocardial changes, diabetic cardiomyopathy, and heart failure.
  • Insulin resistance may drive cardiomyopathy and cardiovascular remodeling, independent of hyperglycemia.

Purpose of the Study:

  • To evaluate the cardiovascular benefits of thiazolidinediones (TZDs) in patients with T2DM and heart failure.
  • To assess the risk-benefit profile of TZDs in this specific patient population.

Main Methods:

  • Review of existing literature on T2DM, heart failure, insulin resistance, and TZD effects.
  • Analysis of cardiovascular outcomes associated with TZD use in diabetic patients.
  • Evaluation of potential adverse effects of TZDs, including fluid retention and weight gain.

Main Results:

  • TZDs demonstrate potential cardiovascular benefits in T2DM patients, including blood pressure reduction, improved endothelial function, and antiatherosclerotic effects.
  • TZDs may improve insulin sensitivity, addressing a key factor in diabetic cardiomyopathy.
  • Adverse effects like edema and weight gain due to fluid retention and fat accumulation are noted concerns, particularly in heart failure patients.

Conclusions:

  • TZDs show promise for managing cardiovascular risks in T2DM patients with heart failure.
  • The potential benefits of TZDs in improving glycemic control and cardiovascular health must be weighed against risks of fluid retention and weight gain.
  • Careful consideration of the risk-benefit ratio is crucial when prescribing TZDs to diabetic patients with comorbid heart failure.

Related Concept Videos

Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...